Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660660 · ClinicalTrials.gov registry record · Phase 4
Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 276
- Enrollment target
NCT00660660 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 276 participants.
The verdict
NCT00660660, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 276 participants
- Enrollment target
Study Summary
The purpose of this research study is to compare the safety and effectiveness (how well the medicine works) of esomeprazole (study drug) to placebo (a capsule that does not contain any medication) taken daily in relieving nighttime heartburn and problems sleeping in patients with gastroesophageal reflux disease (GERD).
Interventions
- DRUG Placebo
- DRUG Esomeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2008-04 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00660660
The ClinicalTrials.gov registry entry for NCT00660660 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00660660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00660660 about?
NCT00660660 is a clinical study titled "Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US". The purpose of this research study is to compare the safety and effectiveness (how well the medicine works) of esomeprazole (study drug) to placebo (a capsule that does not contain any medication) taken daily in relieving nighttime heartburn and problems sleeping in patients with gastroesophageal re...
What is the current status of trial NCT00660660?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 276 participants. The study started on 2008-04. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00660660?
The interventions under investigation include: Placebo (DRUG), Esomeprazole (DRUG).
Who is sponsoring clinical trial NCT00660660?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.